251 related articles for article (PubMed ID: 35186251)
1. Pharmacological management of severe Cushing's syndrome: the role of etomidate.
Pence A; McGrath M; Lee SL; Raines DE
Ther Adv Endocrinol Metab; 2022; 13():20420188211058583. PubMed ID: 35186251
[TBL] [Abstract][Full Text] [Related]
2. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
Engelhardt D; Weber MM
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
[TBL] [Abstract][Full Text] [Related]
3. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
Fleseriu M; Castinetti F
Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
[TBL] [Abstract][Full Text] [Related]
4. Cushing's syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia.
Dzialach L; Sobolewska J; Respondek W; Wojciechowska-Luzniak A; Witek P
Hormones (Athens); 2022 Dec; 21(4):735-742. PubMed ID: 36129663
[TBL] [Abstract][Full Text] [Related]
5. Dimethoxy-etomidate: A Nonhypnotic Etomidate Analog that Potently Inhibits Steroidogenesis.
McGrath M; Ma C; Raines DE
J Pharmacol Exp Ther; 2018 Feb; 364(2):229-237. PubMed ID: 29203576
[TBL] [Abstract][Full Text] [Related]
6. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
7. Drugs in the medical treatment of Cushing's syndrome.
Schteingart DE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
[TBL] [Abstract][Full Text] [Related]
8. Behavioral and steroidogenic pharmacology of phenyl ring substituted etomidate analogs in rats.
McGrath M; Hofmann A; Raines DE
BMC Pharmacol Toxicol; 2019 Aug; 20(1):48. PubMed ID: 31383012
[TBL] [Abstract][Full Text] [Related]
9. Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate.
Heyn J; Geiger C; Hinske CL; Briegel J; Weis F
Pituitary; 2012 Jun; 15(2):117-25. PubMed ID: 21556813
[TBL] [Abstract][Full Text] [Related]
10. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome.
Daniel E; Newell-Price JD
Eur J Endocrinol; 2015 Jun; 172(6):R263-80. PubMed ID: 25637072
[TBL] [Abstract][Full Text] [Related]
11. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.
Feelders RA; Hofland LJ; de Herder WW
Neuroendocrinology; 2010; 92 Suppl 1():111-5. PubMed ID: 20829630
[TBL] [Abstract][Full Text] [Related]
12. [Clinical usefulness of pharmacological treatment of Cushing's syndrome].
Saito J; Nishikawa T
Nihon Rinsho; 1994 Mar; 52(3):793-6. PubMed ID: 8164384
[TBL] [Abstract][Full Text] [Related]
13. New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line.
Fassnacht M; Hahner S; Beuschlein F; Klink A; Reincke M; Allolio B
Eur J Clin Invest; 2000 Dec; 30 Suppl 3():76-82. PubMed ID: 11281374
[TBL] [Abstract][Full Text] [Related]
14. Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics.
Pozza C; Graziadio C; Giannetta E; Lenzi A; Isidori AM
J Oncol; 2012; 2012():685213. PubMed ID: 22934113
[TBL] [Abstract][Full Text] [Related]
15. Advances in medical therapies for Cushing's syndrome.
Tritos NA; Biller BM
Discov Med; 2012 Feb; 13(69):171-9. PubMed ID: 22369976
[TBL] [Abstract][Full Text] [Related]
16. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Lau D; Rutledge C; Aghi MK
Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological therapy of Cushing's syndrome: drugs and indications.
Díez JJ; Iglesias P
Mini Rev Med Chem; 2007 May; 7(5):467-80. PubMed ID: 17504182
[TBL] [Abstract][Full Text] [Related]
18. Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice.
Igaz P; Tömböl Z; Szabó PM; Likó I; Rácz K
Curr Med Chem; 2008; 15(26):2734-47. PubMed ID: 18991633
[TBL] [Abstract][Full Text] [Related]
19. Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature.
Łebek-Szatańska A; Nowak KM; Zgliczyński W; Baum E; Żyłka A; Papierska L
Ther Adv Endocrinol Metab; 2019; 10():2042018819825541. PubMed ID: 30800267
[TBL] [Abstract][Full Text] [Related]
20. Continuous Etomidate for the Management of Cushing's Syndrome Complicated by Pulmonary Nocardiosis.
Hays WB; Czosnowski Q
J Pharm Pract; 2022 Dec; 35(6):1057-1059. PubMed ID: 34056961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
